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Abstract 
Injectable gels have the potential to encapsulate drugs for sustained release of protein 
therapeutics for use in the eye. Hyaluronic acid (HA) is a biodegradable clinically used 
material and poly N-isopropylacrylamide (pNIPAAM) is a stimuli responsive polymer 
that can display a lower critical solution temperature (LCST) at physiological conditions. 
Two gel systems incorporating HA were prepared in the presence of the antibody 
infliximab (INF): i) 1% and 5 % tyramine-substituted HA (HA-Tyr) was enzymatically 
crosslinked in the presence of INF to form HA-Tyr-INF and ii) NIPAAM was chemically 
crosslinked in the presence of HA and INF with 1 and 3% poly(ethylene glycol) 
diacrylate (PEGDA) to form PEGDA-pNIPAAM-HA-INF. The PEGDA-pNIPAAM-HA-
INF hydrogels displayed LCSTs at temperatures ranging from 31.4 ± 0.2 to 35.7 ± 
0.3°C. Although all the gels prepared were injectable, INF-loaded gels with lower 
crosslinking density (1% PEGDA-pNIPAAM-HA and 1% HA-Tyr) showed lower elastic 
(G′) and viscous (G′′) moduli compared to higher crosslinked gels (3% PEGDA-
pNIPAAM-HA-INF and 5% HA-Tyr-INF) resulting in differences in swelling ratio (SR). 
Moduli may be correlated with overall stiffness of the gel. All hydrogels demonstrated 
sustained release of INF in a two-compartment in vitro outflow model of the human 
eye called the PK-Eye. The 1% PEGDA-pNIPAAM-HA-INF hydrogel displayed the 
slowest release (24.9 ± 0.4% INF release by day 9) in phosphate buffered saline (PBS, 
pH 7.4), which is a better release profile than the free drug alone (tested under the 
same conditions). These results suggest that PEGDA-pNIPAAM-HA has potential for 





Many new therapies including therapeutic proteins and cellular therapies are being 
developed to treat blinding diseases for an ageing population. As molecular targets for 
disease continue to be identified, therapeutic proteins are being intensively developed 
because they tend to be fast acting, selective and potent. Currently, antibodies to treat 
age related macular degeneration (AMD) are administered every 4-8 weeks by 
intravitreal (IVT) injections. New dosage forms and drug delivery systems (DDSs) that 
extend the presence of an IVT administered drug are highly sought to (i) to reduce the 
frequency of administration, cumulative doses and undesirable side effects, (ii) to 
ensure a therapeutic dose of a drug is present throughout treatment and (iii) to improve 
patient compliance.1,2 
In situ forming hydrogels have been shown to be a promising method to extend 
the duration of protein.3 Hydrogels can mimic the structure of the extracellular matrix 
(ECM) and have been shown to be biocompatible.4 These three dimensional (3D) 
polymer networks are capable of absorbing a large amount of water and have been 
examined in a number of tissue regeneration applications.4 Hydrogels can be formed 
by physical (e.g. hydrophobic, charge interaction) or chemical crosslinking (e.g. 
covalent) of polymers. Interpenetrating polymer networks (IPN) consists of a mixture 
of two or more polymers and can include polymer networks where one component is 
at least partially interlaced on a molecular segmental scale but not covalently bonded 
to each other.5 Semi-IPNs avoid the restrictions of excessive interpenetrating network 
and can maintain rapid response to external stimuli e.g. temperature change to change 
polymer conformation while extending release profile.6 
Hyaluronic acid (HA) is a pseudo-elastic material with shear thinning properties 
that is capable of gelation. HA stabilises and organises the ECM, regulates cell 
adhesion and motility and mediates cell proliferation and differentiation.7 The 
commercially available form, sodium hyaluronate, has been widely used in 
pharmaceuticals for biomedical applications such as scaffolds for wound healing and 
tissue engineering due to its biocompatible and biodegradable properties.8,9 HA is also 
used in ophthalmic surgery and as a component in implants.8 Unmodified HA is used 
as an adjuvant for ophthalmic drug delivery and enhances the absorption of drugs and 
proteins via the mucosal tissue.10 HA is also used in the fields of viscosurgery and 
viscosupplementation.11 HA is clinically approved for use in eye surgeries including 
cataract removal and corneal transplantation for the repair of a detached retina and 
other eye injuries. HA has been used to prepare IPNs12 and collapsible hydrogels8,13–
16 by either chemically modifying13,17,18 or chemically crosslinking.14,16,19–22 
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HA can be functionalised with tyramine (Tyr) and is commercially available as 
Corgel® BioHydrogel (HA-Tyr) with Tyr substitution from 1-5% on a molar basis.  Tyr 
moieties can then be covalently linked using horseradish peroxidase (HRP) resulting 
in a crosslinked HA hydrogel.17,18,21–25 Crosslinking HA in the presence of the 
therapeutic antibody provides a means to ensure the antibody is mixed in the hydrogel.  
Incubation of an antibody with a hydrogel will not result in sufficient entanglement or 
encapsulation that could be required to prolong the release of the antibody from the 
gel.  
The use of a collapsible thermoresponsive hydrogel provides the potential for 
further prolongation of antibody release from an injected hydrogel formulation. Poly(N-
isopropylacrylamide) (pNIPAAM) is a thermoresponsive polymer26–33 that is 
biocompatible, but it is not biodegradable.34 Incorporation of a HA biodegradable 
component35,36 as an IPN in the pNIPAAM network is one strategy to allow the 
clearance of pNIPAAM.21,34 It is possible that when the biodegradable component HA 
is incorporated within pNIPAAM, the degradation of HA will reduce the overall polymer 
network allowing pNIPAAM oligomers to be soluble and excreted. 
Here we report the preparation of two types of HA hydrogels that have been 
loaded with infliximab (INF) as a model protein. INF binds to tissue necrosis factor 
alpha (TNF-).  Antibodies that target TNF- have the potential to be used to treat 
ocular inflammation.37–39 The hydrogels were (i) a semi-IPN called PEGDA-pNIPAAM-
HA where NIPAAM was chemically crosslinked in presence of HA and INF with 1 and 
3% poly(ethylene glycol) diacrylate (PEGDA) and ii) an enzymatically crosslinked HA-
Tyr-INF that consisted of 1% and 5 % tyramine-substituted HA (HA-Tyr) with INF. Both 
types of hydrogel were prepared in the presence of INF to ensure the antibody was 
entrapped within the hydrogel network. All hydrogels were characterised for their 
rheology, thermoresponsiveness and release kinetics using a two-compartment in vitro 
outflow model of the human eye (the PK-Eye).40 
Materials and Method 
Materials 
Infliximab (Remicade® 100 mg/10 mL, Genentech, South San Francisco, California) 
was obtained from the pooled leftovers from Great Ormond Street Hospital (London, 
UK). N-isopropylacrylamide (NIPAAM), azobisisobutyronitrile (AIBN), ammonium 
persulfate (APS), sodium azide, poly(ethylene glycol) diacrylate (PEGDA, Mn: 575) 
and tetramethylethylene-diamine (TEMED) were purchased from Sigma-Aldrich 
(Gillingham, Dorset, UK). Tyramine-substituted (1 and 5%) hyaluronic acid (Corgel 
Biohydrogel® kit) was purchased from Lifecore Biomedical, LLC (Chaska, Minnesota, 
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USA). Eye drop grade hyaluronic acid (HA, 50 kDa) was purchased from Zhenjiang 
Group, China. Phosphate Buffer Saline (PBS) tablets was purchased from Fisher 
Scientific (Loughborough, Leicestershire, UK). Pierce™ micro bicinchoninic acid 
(BCA) protein assay kit was purchased from Thermo Fisher Scientific (Hertfordshire, 
UK). Visking dialysis membrane tubing (MWCO of 12–14 kDa) was purchased from 
Medicell International Ltd. (London, UK).  
Instrumentation 
A 16-channel Ismatec peristaltic pump (Michael Smith Engineers Ltd., Woking, Surrey, 
UK) was used to maintain fluid flow through the PK-Eye. UV measurements were 
performed using a Hitachi U-2800A spectrometer using Quartz cuvettes (Starna 
Scientific Ltd) with a wavelength range of 200 to 800 nm and a Wallac Victor2 1420 
plate reader. Scanning electron microscopy (SEM) was achieved using a QuantaTM 
200F instrument (FEI Quanta200 FEGESEM, Eindhoven, The Netherlands). Fourier-
transform infrared spectroscopy (FTIR) was recorded with Perkin-Elmer Spectrum 100 
FTIR spectrometer and analysed using Perkin-Elmer Spectrum Express software. 
Differential scanning calorimetry (DSC) experiments were performed on DSC Q2000 
(TA instruments, Waters, LLC) with TA Instruments Universal Analysis 2000 software. 
A VIRTIS-Advantage freeze-dryer was used for freeze-drying. Bohlin CVO rotational 
rheometer (Malvern Instruments Ltd, Malvern, UK) was used to study rheological 
properties of the hydrogels. An Innova®
 
40 incubator (New Brunswick Scientific, Edison, 
USA) was used for incubation of the samples. 
Methods 
Hydrogel preparation  
HA-Tyr gel   
HA-Tyr powder (4.8 kDa, confirmed by matrix-assisted laser desorption/ionisation 
(MALDI-TOF), 1 or 5% Tyr substitution, 10.0 mg, 2.1 × 10-6 moles) was completely 
dissolved in deionised water (0.5 mL). HRP in PBS (0.5 mL, 10.0 UI/mL) was then 
added dropwise over a 10 second period and the reaction solution was gently mixed. 
Hydrogen peroxide (H2O2) in PBS (80 μL, 2.4 × 10-5 moles) was then added and the 
reaction mixture was incubated at 4°C for 24 hours to ensure complete cross-linking 
and polymerisation. INF solution (0.5 mL from 10.0 mg/mL to give a final protein 
concentration of 5.0 mg/mL) was substituted for deionised water to dissolve the HA-
Tyr for the preparation of INF loaded hydrogels.  
The reaction mixture was either stored in the fridge (4˚C) or freeze-dried for 
characterisation (such as fourier transform infrared spectroscopy (FTIR), scanning 
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electron microscopy (SEM) and swelling studies) in tarred 2.0 mL glass vials and the 
product was isolated as a dry, solid white cake. The hydrogels were transferred to 
glass vials with a maximum volume of 2.0 mL for freeze-drying. The samples were 
frozen in dry ice and then transferred to the freeze-drier at -40°C with a condenser 
temperature of -60°C. The vacuum pressure was maintained less than 200 mBar. The 
primary freeze-drying step was at -20°C for 48 hours. The temperature was increased 
to 20°C for 2 hours at the final stage before opening the freeze-drier.  
PEGDA-pNIPAAM-HA gel  
NIPAAM (40.0 mg, 3.5 × 10-4 moles) and HA (50 kDa, 10.0 mg, 2.0 × 10-7 moles) were 
dissolved in deionised water (1.0 mL) in a 7.0 mL vial. PEGDA (Mn 575) was added 
(2.5 μL, 1.0 × 10-5 moles and 5 μL, 5.0 × 10-6 moles corresponding to 1 and 3% PEGDA 
respectively) and gently swirled to ensure mixing. APS (4.0 mg, 1.8 × 10-5 moles, 0.05 
equiv) and TEMED (δ: 0.775 g/mL, 20°C, 20 μL, 1.0 × 10-4 moles, 0.29 equiv) were 
added to the reaction mixture and the vial was capped then the solution was gently 
vortexed for 30 seconds. The mixture was incubated in the fridge at 4°C for 24 hours 
to allow NIPAAM polymerisation and crosslinking to occur. For the INF loaded 
hydrogels, 0.5 mL of the deionised water used to dissolve NIPAAM and HA was 
substituted with INF solution (0.5 mL, 10 mg/mL). The reaction mixture was either 
stored in the fridge (4˚C) or freeze-dried as previously detailed. 
Hydrogel characterisation  
Fourier transform infrared spectroscopy (FTIR) 
Freeze-dried samples were measured with attenuated total reflection (ATR). The 
sample (0.25 mL reaction mixture) was pressed against a high refractive index prism. 
Absorption was measured for wavenumbers between 650 to 4000 cm-1 with 20 scans 
at a resolution of 2.0 cm-1.  
Scanning electron microscopy (SEM)  
Freeze-dried samples (1.0 mL reaction mixture) were cut and adhered onto aluminium 
SEM stubs using carbon-coated double-sided tape prior to SEM analysis. The samples 
were then sputter coated with gold prior to imaging to make them electrically 
conductive.  
Differential scanning calorimetry (DSC)  
The lower critical solution temperature (LCST) was measured using differential 
scanning calorimetery (DSC) at 2.0°C/min from 20 to 50°C. Freeze-dried hydrogels 
(1.0 mL reaction mixture) were transferred to a 7.0 mL glass vial and swollen in water 
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for 24 hours. The water was emptied and the hydrogels were transferred to a weighing 
container. The hydrogel was carefully and gently dabbed dry with tissue and then 
placed in aluminium hermetic pans of known weight. Calibration with Indium (Tm = 
156.6, ∆Hf =28.71 J/g) was performed according to the manufacturer instructions. 
Nitrogen was used as purge gas with a flow rate of 40.0 mL/min for all the experiments. 
The onset temperature of the DSC endothermic peak was considered as the LCST.  
Rheology 
The rheological behavior of the hydrated hydrogels (1.0 mL reaction mixture) was 
investigated under oscillatory shear. A 20 mm diameter plate was used for the analysis 
under auto-stress. Initially amplitude sweep feature determined the linear viscoelastic 
region (LVER) before frequency sweeps at 0.1 - 10 Hz were performed at an 
isothermal temperature of 25°C. Furthermore, the influence of temperature on the 
rheology of the gels was determined by applying oscillatory shear at a fixed frequency 
(1 Hz) across a temperature range (20 – 50°C). The mechanical properties were 
described in terms of elastic modulus (G′, Equation 1a) or viscous modulus (G′′, 
Equation 1b). Complex modulus (G*) measures the gel’s overall rigidity or resistance 
to deformation (Equation 1c). 











𝐺 ∗ = 𝐺′ + 𝑖𝐺′′ c 
Swelling ratio (SR)  
Freeze-dried hydrogel samples (1.0 mL reaction mixture) were weighed and incubated 
in deionised water (2.0 mL) at 25 or 37°C for 48 hours. The samples were then lightly 
wiped and re-weighed. SR was calculated according to the Equation 2, where Ms is 







In vitro release  
The design and validation of the in vitro PK-Eye model has been previously reported.40 
The model comprises of an anterior (0.2 mL) and posterior (4.2 mL) cavity integrated 
within it. A washer with a Visking membrane with a MWCO 12-14 kDa separates the 
two cavities. The inlet port was connected to a peristaltic pump (previously calibrated) 
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with a flow of 2.0 μL/min. One outlet port is present in the anterior cavity for continuous 
sampling. An injection port is present in both cavities (diameter: 2.0-3.0 mm) to allow 
formulation administration into the model. Prior to each experiment, the PK-Eye was 
disassembled and the washer with a fresh Visking membrane was secured in the 
model separating the anterior and posterior cavities. Each model was assembled and 
both cavities were filled with PBS (pH 7.4). The models were immersed in a preheated 
oil bath adjusted to 37°C for 2 hours to equilibrate prior to the release studies. 
Temperature was maintained using a probe connected to the hotplate heater. INF-
loaded hydrogel (1.0 mg, 200 μL) was injected via a 21G needle via the injection port 
of the PK-Eye. Samples were collected from the outflow port at regular intervals and 
stored at 4°C prior to protein quantification. 
Protein quantification 
Protein quantification was conducted with a micro BCA protein assay kit. All released 
samples from the PK-Eye and standards (100 μL) were analysed in a Nunc 96-well 
plate using BCA working reagent (100 μL). A stock solution of INF (200 μg/mL) was 
prepared and serial dilutions with PBS (pH 7.4) were made (0-200 μg/mL). The plates 
were then incubated at 37°C for 2 hours before UV quantification. A calibration curve 
was plotted (R2:0.9998) at 562 nm with a 96 well plate reader and unknown 
concentrations from the PK-Eye were determined by the equation generated. Average 
absorbance of blank (0 μg/mL) was subtracted from each reading. 
 
Data analysis 
All results are presented as the mean and standard deviation (± STD), and data were 
plotted using OriginPro 9.1 (software, Origin lab cooperation, USA). Half-life (t1/2) 
values were calculated according to the best fitting model in OriginPro. Statistical 
significance was determined using one-way ANOVA or Mann Whitney U t-test.  
Probability values less than 0.05 (p<0.05) were considered as indicative of statistically 
significant differences. 
Results and discussion 
Preparation of hydrogels 
Two types of HA in situ hydrogels were prepared. The first, HA-Tyr hydrogel had been 
previously investigated as a biocompatible drug delivery material.41 The effect of 
crosslinking density on the behaviour of the HA-Tyr hydrogels was investigated based 
on the degree of Tyr substitution of HA (1 and 5%). The second, a pNIPAAM-based 
gel was chosen because it possesses thermoresponsive/collapsing property and was 
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expected to sustain the release of the loaded drug.42 Two molar percentages of 
PEGDA crosslinker were utilised (1 and 3%) to observe the effects of crosslinking 
density43 during hydrogel characterisation. 
Initial studies considered pNIPAAM for polymerisation instead of NIPAAM 
monomers. The aim was to polymerise HA-Tyr in the presence of pNIPAAM to produce 
a semi-IPN hydrogel. The gels lacked stability (liquid-like consistency) though the 
method did form hydrogels. Hydration of the gels resulted in leaching out of the 
pNIPAAM into the hydration media resulting in a cloudy solution when placed at 37°C 
(T>LCST). Due to the large size of pNIPAAM and HA-Tyr better mixing was thought to 
resolve this issue. A frost-defrost method44 was used to improve mixing as the defrost 
process ensues better contact of two large molecules. However, this method was 
found not to improve the stability issue of the pNIPAAM gels, therefore,,the results 
discussed in this study are based on hydrogels fabricated from NIPAAM monomers 
Characterisation of hydrogels 
IR spectroscopy and scanning electron microcopy (SEM) 
FTIR results of HA-Tyr and PEGDA-pNIPAAM-HA hydrogels, NIPAAM monomer and 
HA are shown in Figure 1. Formation of PEGDA-pNIPAAM-HA gels is indicated by the 
disappearance of peaks which are characteristic of NIPAAM monomer, including C=C 
(1620 cm-1) and –CH=CH2 (960 and 985 cm-1). The broad C-O stretch attributable to 
HA occurs between 1050-1150 cm-1.  Both HA and NIPAAM have a C=O stretch that 
usually occurs between 1600-1620 cm-1. However, the appearance of a sharp peak at 
1550 cm-1 in PEGDA-pNIPAAm-HA gel (absent in HA only) suggests an N-H stretch 
associated with the amide bond in NIPAAM.28 The sharp peak seen in NIPAAM at 
3400 cm-1 represents N-H in NIPAAM, which broadens in the gel suggesting possible 
interaction with the broad peak attributed to O-H vibration in HA. The spectrum for HA-
Tyr hydrogel remained largely similar to the spectrum of HA only. However, there is a 
visible peak at 2950 cm-1, which represents an aromatic C-H stretch introduced by the 
Tyr group in HA-Tyr. 
Microscopic investigation of PEGDA-pNIPAAM-HA gels showed a structure 
with multiple recurring, well-defined pores of around 1-2 μm (Figure 2A). HA-Tyr 
hydrogels possessed areas of smoother surface with some areas of rough surface and 
irregular, limited larger pores (Figure 2B). Porosity may be attributed to the freeze-
drying process. The loss of initially formed ice crystals creates multiple openings within 
the gel structure. Investigation into the effect of crosslinking density was not conducted, 
however, higher crosslink density was expected to result in less porous gels.21  
Figures 1 and 2 
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Lower critical solution temperature (LCST) 
The thermoresponsiveness of pNIPAAM based gels at physiological temperature is 
driven by collapse to form a more hydrophobic gel at a glass transition midpoint (Tg) 
known as the LCST.45 DSC was used to determine the LCST of the prepared pNIPAAM 
hydrogels with and without INF.  
The LCST was 31.4 ± 0.2 (heat flow: 0.020 W/g) and 34.2 ± 0.1°C (heat flow: 
0.008 W/g) for 1 and 3% of pNIPAAM-PEGDA-HA hydrogels respectively (Figure 3A). 
In a previous study conducted in our laboratory, LCST values ranged from 34.3 ± 0.2 
to 36.2 ± 0.2°C (p<0.05) for PEGDA amounts from 2-6% (with pNIPAAM-PEGDA 
hydrogels).32 Isopropyl groups predominate above the LCST leading to an aggregation 
mechanism that results in the overall domination of hydrophobicity.46 The polymer 
chain retracts from the surrounding solvent in a repulsive force manner. There is an 
expulsion of water content followed by a slower release of contents above the LCST.47 
LCST values of 34.1 ± 0.1 and 35.7 ± 0.3°C were recorded for 1 and 3% 
pNIPAAM-PEGDA-HA-INF hydrogels (Figure 3B). Protein loading resulted in broader 
response peaks/Tg. The slight increase in the LCST is thought to be due to the 
hydrophilic nature of INF.14,29,48,49 Interestingly the less crosslinked gels (both with and 
without protein) appeared to show sharper thermoresponsiveness seen as higher 
change in heat flow (0.0070 W/g cf. 0.0037 W/g). pNIPAAM-PEGDA-HA gels 
appeared clear at room temperature (25°C) and visibly changed to a white gel when 
placed above its LCST (Figure 3C). 
Figure 3 
Rheological behavior of hydrogels 
Rheological properties were expressed as two dynamic mechanical properties in this 
study i.e. elastic and viscous modulus. Elastic modulus (G′) refers to the energy stored 
within a gel that has been exposed to deformation i.e. oscillatory shear in this case. It 
is a measure of the elasticity of gels or the rigidity of gels derived from elastic 
deformation. Viscous modulus (G′′) refers to the energy lost in a material following 
deformation.50  
G′ was found to be higher than G′′ in all the empty gels produced suggesting 
that the G′ pre-dominates and therefore, all gels demonstrated properties of a 
viscoelastic solid51 (Figures 4A and B). Higher cross-linking concentrations (5% HA-
Tyr and 3% PEGDA-pNIPAAM-HA gels) contributed to higher moduli and therefore, 
higher overall rigidity. Increased frequency of oscillation had little influence on the 
moduli of highly crosslinked hydrogels (5 % HA-Tyr and 3 % PEGDA-pNIPAAM-HA). 
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Although all the prepared gels were injectable, it is expected that the injectablility of 
gels inversely correlates with the overall rigidity of the gels (G*).52 
A significant drop in G′′ was observed for all the INF loaded hydrogels, 
especially with 1% PEGDA-pNIPAAM-HA-INF and 1% HA-Tyr-INF. These two 
hydrogels also showed a higher frequency dependent change in moduli. Interestingly, 
1% PEGDA-pNIPAAM-HA-INF showed a drop in G′′ (Figure 4B) at the highest 
oscillation frequency suggesting a higher tendency to “yield” when such a large 
molecule such as INF is incorporated within the matrix (perhaps due to increased 
disentanglement within the gel network). 
Figure 4C shows the temperature-dependent change in the moduli (G*) of 
pNIPAAM-based hydrogels. A steep increase in G* is seen at approximately 33°C with 
the empty gels and 34°C with the INF-loaded hydrogels. The increased moduli is 
attributed to the temperature-dependent sol-gel transition of pNIPAAM when T>LCST 
causing its gels to have higher G* compared to HA-Tyr gels, which are not 
thermosensitive. Overall, this rheology study showed that higher crosslink density led 
to increased rigidity of the hydrogels and that the incorporation of INF within the gels 
only had an influence in the moduli of lower cross-linked hydrogel formulation, which 
demonstrated shear thinning behaviour.  
Figure 4 
Swelling ratio (SR) measurements 
SR gives potential insight into the release kinetics of drugs loaded within hydrogels 
and mechanical structure of the hydrogels.21 Empty HA-Tyr hydrogels showed higher 
SR values compared to pNIPAAM hydrogels at both 25 and 37°C (Figure 5A). The 
higher SR of HA-Tyr can be due to its multiple OH groups,12 which can lead to stronger 
attraction with water molecules as compared to the hydrophobic isopropyl groups 
present in NIPAAM.  
A SR of 56.5 ± 0.1 and 49.6 ± 0.8 was observed for the 1 and 5% HA-Tyr 
hydrogels respectively, whereas a SR of 24.2 ± 1.2 and 20.5 ± 1.4 was seen for 1 and 
3% pNIPAAM-HA hydrogels at 25°C respectively. There was no significant difference 
(p>0.05) in the intra SR i.e. within the pNIPAAM-HA or HA-Tyr hydrogels. However, 
there was a significant difference (p<0.05) in swelling when gels are inter-compared.  
A SR of 4.2 ± 1.2 and 3.7 ± 1.8 for empty 1 and 3% pNIPAAM-HA hydrogels 
was observed at 37°C respectively. There were significant differences in SR (p<0.05) 
when the temperature increased to 37°C. The drop in SR can be attributed to the 
collapsing property of pNIPAAM. A rearrangement occurs at 37°C causing the 
hydrophobic isopropyl group to predominate leading to an expulsion of water content 
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previously contained in the hydrogel.45 An average SR of 53.2 ± 2.6 and 51.7 ± 6.8 
was observed for 1 and 5% HA-Tyr gels respectively indicating that there was no 
significant difference (p<0.05) in the SR at 37°C. 
The incorporation of INF (5.0 mg/mL) reduced the SR in all hydrogel 
formulations (Figure 5B). The reduction in residential space for water in presence of 
INF within the hydrogel pores could have contributed to the decrease in SR.4 Another 
possible reason could be due to INF mediated disruption of interaction with water 
molecules. A SR of 29.4 ± 0.3:31.8 ± 1.9 was seen with 1% HA-Tyr hydrogel at 25:37°C 
respectively, 10.2 ± 0.1:10.0 ± 0.2 for 5% HA-Tyr-INF hydrogels respectively. There 
was no significant difference (p>0.05) in SR of each hydrogel at these two 
temperatures. A SR of 21.5 ± 0.7:1.7 ± 0.2 was seen with 1% pNIPAAM-HA-INF at 
25:37°C respectively, whereas a SR of 8.3 ± 0.2:2.1 ± 0.1 for 3% pNIPAAM-HA-INF 
respectively. The reduction in SR was significant (p<0.05), which could be attributed 
to the thermoresponsive properties of pNIPAAM.  
Figure 5 
 
In vitro release kinetics using the PK-Eye  
Experiments using the PK-Eye40 were conducted to determine which gel formulation 
could effectively extended the release profile of INF. The PK-Eye is a two-compartment 
model that mimics certain properties of the human eye.40 One key advantage of the 
PK-Eye was that it provides a distinct outflow so that the quantification of INF could be 
easily calculated. The pump flow system provided fresh buffer as opposed to a single-
compartment (non-outflow) release system that involved dilution of the drug with each 
sampling due to addition of fresh buffer for volume correction. INF (1.0 mg, 200 μL) 
loaded hydrogels were injected in the posterior cavity of the PK-Eye containing PBS 
(pH 7.4) and outflow samples from the anterior cavity was analysed with the BCA 
assay. 
An initial screening study was conducted to observe the difference in INF 
release kinetics. INF released was 74.2 ± 0.4 and 71.4 ± 0.2% for the 1 and 5% HA-
Tyr gels respectively by day 12 (top panel, Figure 6). INF released was 50.4 ± 0.8 and 
40.9 ± 0.5% for the 1 and 3% pNIPAAM-HA gels respectively by day 12 (no significant 
difference). The data generated also suggests that crosslinking had not exceeded a 
point where the hydrogels possess such a dense structure that loading of INF becomes 
significantly lower.  
Following the screening study, two formulations were selected for repeated 
release studies (bottom panel, Figure 6). Selection was conducted based on the 
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rheology of the formulations since cross-linking density did not appear to significantly 
impede the release kinetics of each type of hydrogel. Gels with lower cross linking 
were preferred for the release study on the basis of overall lower moduli (Figure 4) 
being related to improved injectability. However, the 1% HA-Tyr-INF hydrogel was 
discontinued for further release studies due to its almost full liquid-like state, which 
affected handling (e.g. washing step and further characterisation). Confirmed removal 
of cross-linking reagents will be necessary for further development. 
The release study (bottom panel, Figure 6) demonstrated a similar 2:1 
(approximate) release trend seen in the initial screening (top panel, Figure 6). INF 
released was 45.4 ± 0.3 and 24.9 ± 0.4 % at day 9 for 5 % HA-Tyr and 1 % PEGDA-
HA-pNIPAAM respectively. The difference in percentage protein release was 
statistically significant (p=0.0125, n=3). The anterior concentration of INF (Figure 6) 
suggests that 1 % PEGDA-pNIPAAM-HA-INF showed less of a burst release, with 
concentration values of 10-20 µg/mL throughout the 9 days. 
The results were promising as the experiment was conducted in PBS and it is 
expected that proteins will diffuse more slowly in a more viscous environment (such as 
simulated vitreous).40 Previous studies of ranibizumab (50 kDa) and bevacizumab (150 
kDa) in PBS have a reported t1/2 of 1.5 ± 0.6 and 1.2 ± 0.1 days respectively with almost 
90-100% protein clearance within 7-10 days.40 These results indicate that INF (150 
kDa) loaded hydrogels do show sustained release in the posterior cavity. The 
difference in SR of both HA-Tyr and PEGDA-pNIPAAM-HA hydrogels could have 
contributed to the faster INF release in the former. HA-Tyr gels had a higher SR (Figure 
5B) than PEGDA-pNIPAAM-HA based gels. Swelling may be seen as a dissolution 
mechanism that promotes the osmotic drive of encapsulated INF from the hydrogel 
into the release media.21 The physiochemical property of pNIPAAM is such that above 
LCST, it shrinks due to domination of hydrophobic groups. Essentially the collapse of 
pNIPAAM gels appears to result in a depot-like effect resulting in an even slower 
release of INF4 perhaps due to the erosion of the gel. The slow release of pNIPAAM 
hydrogel is well known and it has been proposed that grafting NIPAAM with a 
hydrophilic compound would be necessary to hasten the release of drug loaded.53  
Figure 6 
Conclusions 
One of the most important goals in ophthalmic drug development is to extend the 
therapeutic level of drugs, especially proteins and antibodies, in the posterior segment 
to treat blinding diseases. With an ageing population and with people living longer, 
there is a need to develop extended formulations for ocular use. In situ-forming 
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injectable gels have long been examined to encapsulate drugs for sustained local 
release. Hydrogels when used in a drug delivery system to prolong the release of a 
drug typically contain a lot of water and are often burdened by an initial burst release 
of the drug. The release of a drug in a burst can be of an advantage clinically as a 
‘loading dose’, but is more often a major concern because it may shorten total duration 
of release and result in dose-dependent adverse effects. HA-Tyr and PEGDA-
pNIPAAM-HA were prepared and loaded with INF as a model protein. 
Thermoresponsive properties of pNIPAAM-based hydrogels were retained even after 
the addition of INF. The crosslinking density of the hydrogels correlated with SR and 
overall modulus of the gels. Highly crosslinked gels had a lower SR but showed more 
rigidity. The PK-Eye helps estimate the release profiles of long lasting dosage forms 
during preclinical research that may accelerate development. The PK-Eye was 
designed to be simple and practical to use to allow for iterative processes to occur so 
that formulations can be optimised efficiently and while minimising the use of animal 
models for suboptimal preclinical candidates. All hydrogels showed sustained release 
profiles as compared to the protein alone (previously tested) when conducted in the 
PK-Eye. PEGDA-pNIPAAM-HA showed slower release profile as compared to HA-Tyr 
hydrogels. 
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